Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

A new GLP-1 pill from Eli Lilly has shown positive results in clinical trials. New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Eli Lilly (LLY) announced on Thursday that its weight loss pill has succeeded Phase 3 trials on Type 2 diabetes patients, ...

An experimental pill may work just as well as injectable, Ozempic-style drugs at treating type 2 diabetes, early trial results suggest. GLP-1 agonists are best known as weight-loss drugs ...

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...